A Study of Pyrotinib Combined With Capecitabine for Metastatic HER-2 Positive Colorectal Cancer

NCT04227041 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

UNKNOWN

Status

34

Enrollment

OTHER

Sponsor class

Conditions

HER-2 Positive Colorectal Cancer

Interventions

DRUG: Pyrotinib in combination with capecitabine

Sponsor

Qingdao Zhixin Health Technology Co., Ltd.

Collaborators

[object Object]